Quicker bringing to market of orphan medicinal products

The European pilot programme “Adaptive Pathways” aims to make it quicker to bring to market medicines aimed at a limited number of diseases while guaranteeing their safety. Pharmaceutical products will be assessed after the initial clinical trials. According to Tomas Salmonson, President of the Committee for Medicinal Products for Human Use, the scheme will apply to many medicines. Eight treatments selected from the 58 medicines considered for the project are following the test programme.